Congress extended federal funding through December 11, 2026, leaving FY 2027 appropriations unresolved until the post-election lame-duck session. Meanwhile, NIH grant oversight and predictable research funding remain important issues for pediatric research.
CNS continued its vaccine advocacy, submitting comments to HHS on September 15 urging clear, evidence-based recommendations and timely vaccination, particularly for children with complex neurological conditions. Congressional scrutiny of federal vaccine policy and FDA commissioner nominee Dr. Heidi Overton also continued.
On September 29, CNS representatives met with Sen. Tammy Duckworth’s office to discuss federal priorities affecting children with neurological conditions, including sustained NIH research funding, rare neurological diseases, and continued telehealth access.
Read the Full September Update